<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903158</url>
  </required_header>
  <id_info>
    <org_study_id>SHR3680-BA</org_study_id>
    <nct_id>NCT04903158</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study of SHR3680</brief_title>
  <acronym>SHR-3680</acronym>
  <official_title>A Single-Center, Single-Dose, Randomized, Open-Label, Parallel Study of Relative Bioavailability With Oral Administration of New and Old Formulations of SHR3680 Tablets in Healthy Male Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, single-dose, randomized, open-label, parallel sstudy to evaluate the&#xD;
      relative bioavailability of new and old formulations of SHR3680 tablets in healthy male&#xD;
      subjects under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Actual">March 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fr</measure>
    <time_frame>predose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 168 and 336 hour after dosing</time_frame>
    <description>Fr=AUC (test formulation)/AUC (reference formulation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>predose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 168 and 336 hour after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>predose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 168 and 336 hour after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>predose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 168 and 336 hour after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>predose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 168 and 336 hour after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>predose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 168 and 336 hour after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd</measure>
    <time_frame>predose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 168 and 336 hour after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>predose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 168 and 336 hour after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events/serious adverse events (based on NCI-CTCAE 5.0)</measure>
    <time_frame>From the screening to the scheduled last visit day (Day 49±1 after dosing)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test formulation of SHR3680</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Reference formulation of SHR3680.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>test SHR3680 tablets</intervention_name>
    <description>Subjects receiving a single oral dose of SHR3680 tablets with 240mg (80mg*3)</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reference SHR3680 tablets</intervention_name>
    <description>subjects receiving a single oral dose of SHR3680 tablets with 240mg (100mg*2+20mg*2).</description>
    <arm_group_label>Reference group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign the informed consent before the trial, and fully understand the trial content,&#xD;
             process and possible adverse reactions;&#xD;
&#xD;
          2. Ability to complete the study as required by the protocol;&#xD;
&#xD;
          3. Healthy male or female subjects aged 18 to 45 (including 18 and 45) at the date of&#xD;
             signing the informed consent, and less than 10-year between minimum age and maximum&#xD;
             age of the whole subjects;&#xD;
&#xD;
          4. Body weight ≥ 50 kg, and body mass index (BMI) within the range of 19 ~ 26 kg /m2&#xD;
             (including 19 and 26);&#xD;
&#xD;
          5. Agreement to avoid sperm donation for 3 months days after the dose of SHR3680;&#xD;
&#xD;
          6. Glomerular filtration rate (GFR) ≥ 90mL / min / 1.73m2 (see Appendix 1 of the clinical&#xD;
             trial protocol for the calculation formula of GFR);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any history of epilepsy, including childhood febrile seizures, loss of consciousness,&#xD;
             transient ischemic attacks or any conditions that may lead to seizures, such as&#xD;
             cerebrovascular disease, brain injury, stroke or brain cancer, etc;&#xD;
&#xD;
          2. Any subject who had any clinically significant acute diseases within one month before&#xD;
             screening, including fever or fever as his clinical symptoms, virus, bacteria&#xD;
             (including upper respiratory tract infection) or fungi (non-skin) infections;&#xD;
&#xD;
          3. Loss of more than 400 mL blood during the 3 months before the trial (eg, as a blood&#xD;
             donor);&#xD;
&#xD;
          4. Allergic constitution;&#xD;
&#xD;
          5. History of drug use, or drug abuse screening positive;&#xD;
&#xD;
          6. Alcoholic or often drinkers;&#xD;
&#xD;
          7. A smoker with 5 cigarettes per day for more than 90 days;&#xD;
&#xD;
          8. Positive serology for hepatitis B surface antigen (HBsAg) and HCV (healthy&#xD;
             participants), anti-treponema pallidum virus (TP), or antihuman immunodeficiency virus&#xD;
             (HIV) Type 1 and Type 2 (all subjects);&#xD;
&#xD;
          9. Use of any drugs or substances known to be inhibitors or inducers of CYP enzymes&#xD;
             within 90 days from the first dose or 5 half-lives, if known, of the drugs or&#xD;
             substances, whichever is greater, prior to SHR3680 administration and during the&#xD;
             study.&#xD;
&#xD;
         10. A clear medical history of important primary organ diseases such as nervous system,&#xD;
             cardiovascular system, urinary system, digestive system, respiratory system,&#xD;
             metabolism and musculoskeletal system.&#xD;
&#xD;
         11. Abnormal clinical laboratory tests and clinical significance judged by the&#xD;
             investigator or other clinical findings showing the following diseases, including but&#xD;
             not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor,&#xD;
             lung, immune, mental or cardiovascular and cerebrovascular diseases.&#xD;
&#xD;
         12. From 48 hours before taking the study drug to the end of the study, any subject&#xD;
             refused to stop using any drinks containing methylxanthine (such as coffee, tea, cola,&#xD;
             chocolate, etc.), alcoholic drinks and any fruit juice; they took drinks or foods&#xD;
             containing grapefruit 7 days before the first administration of the study drug;&#xD;
&#xD;
         13. Those who received vaccination within 3 months before screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

